Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...
Gilead reports positive HIV PrEP data for lenacapavir
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
Morningstar7d
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic – Full Results From PURPOSE 2 Study Exploring ...
Code Pharma’s Gammora® Demonstrates Highly Favorable Outcomes Toward a Potential Cure for HIV
Code Pharma today announced positive eight-week results for human immunodeficiency virus (HIV)-drug Gammora®, showing ...
Morningstar7d
ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow
Key data to be presented at HIV Glasgow 2024 by ViiV Healthcare and its study partners will include: Analysis of cabotegravir + rilpivirine long-acting (CAB+RPV LA) in the real-world and across ...
Gilead to present HIV research findings at conference
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
GB News on MSN2d
Princess Anne dealt blow as royal's plane 'struggles to land'
Princess Anne has been dealt a blow as the royal's plane "struggled to land" amid extreme weather conditions. The Princess ...
Business Insider3d
ViiV Healthcare announces data on Dovato from DOLCE study
These data were presented at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November. DOLCE is a randomised, open-label, multicentre study assessing the efficacy and safety of DTG/3TC ...
Nasdaq7d
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
“Our contributions to HIV Glasgow 2024 demonstrate that people are at the center of all we do at Gilead. The breadth and depth of Gilead’s work underscore our commitment to driving the next ...
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...